Role of paraoxonase-1 in bone anabolic effects of parathyroid hormone in hyperlipidemic mice

Biochemical and Biophysical Research Communications

Volumn 431, Issue 1, 2013, Pages 19-24

  Lu, Jinxiu ^a   Cheng, Henry ^b   Atti, Elisa ^b   Shih, Diana M ^b   Demer, Linda L ^a,b,c   Tintut, Yin ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California   (United States)

Author keywords

Hyperlipidemia; Intermittent; Oxidant stress; Paraoxonase 1; Parathyroid hormone

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ARYLDIALKYLPHOSPHATASE 1; BONE MORPHOGENETIC PROTEIN 2; HIGH DENSITY LIPOPROTEIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR 1; SCLEROSTIN; TRANSCRIPTION FACTOR FKHR; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSYNTHESIS; BONE MINERAL; CALVARIA; CELL DIFFERENTIATION; CONTROLLED STUDY; CORTICAL BONE; DIAPHYSIS; FEMUR; GENE EXPRESSION; GENE OVEREXPRESSION; HYPERLIPIDEMIA; LIPID OXIDATION; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THICKNESS; TRABECULAR BONE;

ANABOLIC AGENTS; ANIMALS; ARYLDIALKYLPHOSPHATASE; BONE AND BONES; GENE EXPRESSION; HUMANS; HYPERLIPIDEMIAS; LIPIDS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OSTEOBLASTS; OSTEOCYTES; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARATHYROID HORMONE; RECEPTORS, LDL;

MUS;

EID: 84873082115     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.12.114     Document Type: Article

References (37)

1. Primo-Parmo S.L., Sorenson R.C., Teiber J., La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996, 33:498-507.
2. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991, 286:152-154.
3. Mackness B., Quarck R., Verreth W., Mackness M., Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1545-1550.
4. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 1995, 96:2882-2891.
5. Bhattacharyya T., Nicholls S.J., Topol E.J., Zhang R., Yang X., Schmitt D., Fu X., Shao M., Brennan D.M., Ellis S.G., Brennan M.L., Allayee H., Lusis A.J., Hazen S.L. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008, 299:1265-1276.
6. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287.
7. Tward A., Xia Y.R., Wang X.P., Shi Y.S., Park C., Castellani L.W., Lusis A.J., Shih D.M. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002, 106:484-490.
8. Morgantini C., Imaizumi S., Grijalva V., Navab M., Fogelman A.M., Reddy S.T. Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes. Diabetes 2010, 59:3223-3228.
9. Navab M., Berliner J.A., Watson A.D., Hama S.Y., Territo M.C., Lusis A.J., Shih D.M., Van Lenten B.J., Frank J.S., Demer L.L., Edwards P.A., Fogelman A.M. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol. 1996, 16:831-842.
10. Towler D.A. Oxidation, inflammation, and aortic valve calcification peroxide paves an osteogenic path. J. Am. Coll. Cardiol. 2008, 52:851-854.
11. Brodeur M.R., Brissette L., Falstrault L., Ouellet P., Moreau R. Influence of oxidized low-density lipoproteins (LDL) on the viability of osteoblastic cells. Free Radic. Biol. Med. 2008, 44:506-517.
12. Pirih F., Lu J., Ye F., Bezouglaia O., Atti E., Ascenzi M., Tetradis S., Demer L., Aghaloo T., Tintut Y. Adverse effects of hyperlipidemia on bone regeneration and strength. J. Bone Miner. Res. 2012, 27:309-318.
13. Hirasawa H., Tanaka S., Sakai A., Tsutsui M., Shimokawa H., Miyata H., Moriwaki S., Niida S., Ito M., Nakamura T. ApoE gene deficiency enhances the reduction of bone formation induced by a high-fat diet through the stimulation of p53-mediated apoptosis in osteoblastic cells. J. Bone Miner. Res. 2007, 22:1020-1030.
14. Hjortnaes J., Butcher J., Figueiredo J.L., Riccio M., Kohler R.H., Kozloff K.M., Weissleder R., Aikawa E. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur. Heart J. 2010, 31:1975-1984.
15. Tintut Y., Morony S., Demer L.L. Hyperlipidemia promotes osteoclastic potential of bone marrow cells ex vivo. Arterioscler. Thromb. Vasc. Biol. 2004, 24:e6-e10.
16. Kawai K., Maruno H., Watanabe Y., Hirohata K. Fat necrosis of osteocytes as a causative factor in idiopathic osteonecrosis in heritable hyperlipemic rabbits. Clin. Orthop. Relat. Res. 1980, 273-282.
17. Watanabe Y., Kawai K., Hirohata K. Histopathology of femoral head osteonecrosis in rheumatoid arthritis: the relationship between steroid therapy and lipid degeneration in the osteocyte. Rheumatol. Int. 1989, 9:25-31.
18. Ambrogini E., Almeida M., Martin-Millan M., Paik J.H., Depinho R.A., Han L., Goellner J., Weinstein R.S., Jilka R.L., O'Brien C.A., Manolagas S.C. FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab. 2010, 11:136-146.
19. Rached M.T., Kode A., Xu L., Yoshikawa Y., Paik J.H., Depinho R.A., Kousteni S. FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts. Cell Metab. 2010, 11:147-160.
20. Parhami F., Jackson S.M., Tintut Y., Le V., Balucan J.P., Territo M., Demer L.L. Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells. J. Bone Miner. Res. 1999, 14:2067-2078.
21. Parhami F., Morrow A.D., Balucan J., Leitinger N., Watson A.D., Tintut Y., Berliner J.A., Demer L.L. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler. Thromb. Vasc. Biol. 1997, 17:680-687.
22. Tintut Y., Parhami F., Tsingotjidou A., Tetradis S., Territo M., Demer L.L. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. J. Biol. Chem. 2002, 277:14221-14226.
23. Lindsay R., Nieves J., Formica C., Henneman E., Woelfert L., Shen V., Dempster D., Cosman F. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550-555.
24. Iida-Klein A., Zhou H., Lu S.S., Levine L.R., Ducayen-Knowles M., Dempster D.W., Nieves J., Lindsay R. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J. Bone Miner. Res. 2002, 17:808-816.
25. Huang M.S., Lu J., Ivanov Y., Sage A.P., Tseng W., Demer L.L., Tintut Y. Hyperlipidemia impairs osteoanabolic effects of PTH. J. Bone Miner. Res. 2008, 23:1672-1679.
26. Sage A.P., Lu J., Atti E., Tetradis S., Ascenzi M.G., Adams D.J., Demer L.L., Tintut Y. Hyperlipidemia induces resistance to PTH bone anabolism in mice via oxidized lipids. J. Bone Miner. Res. 2011, 26:1197-1206.
27. Huang M.S., Morony S., Lu J., Zhang Z., Bezouglaia O., Tseng W., Tetradis S., Demer L.L., Tintut Y. Atherogenic phospholipids attenuate osteogenic signaling by BMP-2 and parathyroid hormone in osteoblasts. J. Biol. Chem. 2007, 282:21237-21243.
28. Huang M.S., Sage A.P., Lu J., Demer L.L., Tintut Y. Phosphate and pyrophosphate mediate PKA-induced vascular cell calcification. Biochem. Biophys. Res. Commun. 2008, 374:553-558.
29. Morony S., Tintut Y., Zhang Z., Cattley R.C., Van G., Dwyer D., Stolina M., Kostenuik P.J., Demer L.L. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008, 117:411-420.
30. Navab M., Hama S.Y., Hough G.P., Subbanagounder G., Reddy S.T., Fogelman A.M. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J. Lipid Res. 2001, 42:1308-1317.
31. Kulkarni N.H., Halladay D.L., Miles R.R., Gilbert L.M., Frolik C.A., Galvin R.J., Martin T.J., Gillespie M.T., Onyia J.E. Effects of parathyroid hormone on Wnt signaling pathway in bone. J. Cell. Biochem. 2005, 95:1178-1190.
32. Takase H., Yano S., Yamaguchi T., Kanazawa I., Hayashi K., Yamamoto M., Yamauchi M., Sugimoto T. Parathyroid hormone upregulates BMP-2 mRNA expression through mevalonate kinase and Rho kinase inhibition in osteoblastic MC3T3-E1 cells. Horm. Metab. Res. 2009, 41:861-865.
33. Xiong J., Onal M., Jilka R.L., Weinstein R.S., Manolagas S.C., O'Brien C.A. Matrix-embedded cells control osteoclast formation. Nat. Med. 2011, 17:1235-1241.
34. Jilka R.L., Almeida M., Ambrogini E., Han L., Roberson P.K., Weinstein R.S., Manolagas S.C. Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration. Aging Cell 2010, 9:851-867.
35. Yu S., Franceschi R.T., Luo M., Fan J., Jiang D., Cao H., Kwon T.G., Lai Y., Zhang J., Patrene K., Hankenson K., Roodman G.D., Xiao G. Critical role of activating transcription factor 4 in the anabolic actions of parathyroid hormone in bone. PLoS One 2009, 4:e7583.
36. Robling A.G., Kedlaya R., Ellis S.N., Childress P.J., Bidwell J.P., Bellido T., Turner C.H. Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice. Endocrinology 2011, 152:2963-2975.
37. Nakao Y., Koike T., Ohta Y., Manaka T., Imai Y., Takaoka K. Parathyroid hormone enhances bone morphogenetic protein activity by increasing intracellular 3',5'-cyclic adenosine monophosphate accumulation in osteoblastic MC3T3-E1 cells. Bone 2009, 44:872-877.